Date: 2011-10-20
Type of information: R&D agreement
Compound: active molecules interacting with Cbl-b target
Company: Evotec (Germany) Apeiron Biologics (Austria)
Therapeutic area: Cancer - Oncology
Type agreement: research - R&D
Action mechanism:
Disease:
Details: Evotec and Apeiron Biologics have entered into a further discovery project on the Cbl-b target. Cbl-b plays a role in both the adaptive and the innate immune system and its manipulation therefore can effectively enhance anti-tumor activities both for tumor antigen-specific cells and for those recognizing general features of tumor cells. Evotec will apply their skills and proprietary technologies in cellular assay development and ultra-high throughput screening (uHTS) to identify biologically active molecules from its corporate library that interact with Cbl-b. The aim of the collaboration will be to take compounds identified by Evotec as being active against this target or other relevant targets and further jointly optimize them as basis for formal preclinical and clinical development.
Financial terms: Financial details were not disclosed.
Latest news:
